Start › Chłoniak nieziarniczy › Teksas › Houston
Badania kliniczne dla Chłoniak nieziarniczy w mieście Houston, TX
31 badań dla Chłoniak nieziarniczy szuka uczestników w ośrodkach w mieście Houston i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekrutacjaFaza 1/2
- Md Anderson Cancer Center, Houston
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RekrutacjaFaza 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RekrutacjaFaza 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RekrutacjaFaza 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekrutacjaBadanie obserwacyjne
- Texas Children's Hospital, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekrutacjaFaza 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekrutacjaFaza 1
- Baylor College of Medicine, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekrutacjaFaza 1
- Md Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RekrutacjaFaza 1/2
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RekrutacjaFaza 2
- Research Site, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RekrutacjaFaza 1
- Clinical Trial Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekrutacjaFaza 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekrutacjaFaza 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekrutacjaFaza 3
- MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
RekrutacjaFaza 2
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekrutacjaFaza 2
- The University of Texas MD Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekrutacjaBadanie obserwacyjne
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
RekrutacjaFaza 1
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- i 1 więcej
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RekrutacjaFaza 2
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RekrutacjaFaza 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekrutacjaFaza 4
- University of Texas MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekrutacjaFaza 4
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekrutacjaFaza 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RekrutacjaFaza 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RekrutacjaFaza 1/2
- University of Texas MD Anderson Cancer Center, Houston
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
Badania dla Chłoniak nieziarniczy w innych miastach
- New York City, NY31 badań
- Boston, MA26 badań
- Nashville, TN21 badań
- Philadelphia, PA20 badań
- Baldwin Park, CA19 badań
- Washington, DC18 badań
- Chicago, IL18 badań
- Atlanta, GA18 badań
- Milwaukee, WI18 badań
- Columbus, OH18 badań
- Dallas, TX17 badań
- Seattle, WA16 badań
Inne badania w mieście Houston
- Niedrobnokomórkowy rak płuca145 badań
- Rak piersi126 badań
- Nowotwory (wszystkie typy)121 badań
- Nowotwór przerzutowy104 badań
- Rak jelita grubego i odbytnicy102 badań
- Rak jajnika89 badań
- Ostra białaczka szpikowa85 badań
- Rak płuc78 badań
- Rak prostaty76 badań
- Rak endometrium68 badań
- Rak trzustki61 badań
- Czerniak59 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.